AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06690528 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection of both the primary tumor and liver metastases
Description: Surgical resection of both the primary tumor and liver metastases. The surgical approach, extent of resection, and perioperative management will follow the standard protocols at each participating center. Venous vascular resections might be performed to reach radicality. Either standard or parenchyma sparing liver resections might be performed for resection of the liver metastases. Alternatively, needle ablation/microwave on the liver lesions is possible for lesions \<20 mm if technically feasible. Post-operative chemotherapy and/or radiotherapy could be administered as per multi-disciplinary decision based on case-by-case evaluation.
Study NCT05902754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Generally Recognized as Safe - Sulforaphane
Description: Participants will be asked to maintain the same food ingestion habits as before the study and take 2 tablets of Sulforaphane a day with a meal for 28 days.
Study NCT05902754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to maintain the same food ingestion habits as before the study and take 2 tablets of placebo a day with a meal for 28 days.
Study NCT05365880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liquid Lidocaine
Description: The investigational treatment is 2 mL of aqueous 2% lidocaine.
Study NCT05365880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The active placebo comparator will be provided to participant.
Study NCT04835597 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral Assessment
Description: Complete movement assessment
Study NCT04835597 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: SAE data is collected
Study NCT06439771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL202 should be intravenously infused
Description: For each patient, YL202 should be intravenously infused over 60±10 min.
Study NCT05894564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days.
Study NCT05894564 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
Study NCT06369662 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometric immunophenotyping
Description: CD155 expression by flow cytometric immunophenotyping
Study NCT06369662 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood count
Description: Complete blood count with peripheral blood smear examination
Study NCT06369662 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bone marrow aspiration
Description: Bone marrow aspiration at both diagnosis and follow up of patients
Study NCT06369662 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cytogenetic testing
Description: Karyotyping or AML fluorescence in situ hybridization (FISH) panel for diagnosis and risk stratification of AML patients
Study NCT06369662 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FLT3-ITD using High resolution melting curve (HRM) analysis
Description: Detection of FLT3-ITD mutation in AML patinets
Study NCT06053320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prism adaptation therapy (PAT) + Electrical stimulation (E-stim)
Description: PAT requires one to wear prism lenses while making arm-reaching movements toward visual targets. For treating left-sided neglect, a person wears the prism lenses that shift the visual field, including the images of the target and of one's own reaching arm, certain degrees to the right depending on the diopter of the lens (e.g., the 20-diopter lens shifts the visual field by 11.4 degrees). The visual system adapts over the repetitive practice of the arm reaching toward the target. The person eventually achieves success with a leftward movement reaching the actual target. Electrical stimulation (E-stim) involves parameters and settings commonly used in clinical practice as well as research for pain relief and other applications, commonly referred to as transcutaneous electrical nerve stimulation (TENS). TENS and E-stim are delivered using FDA-approved, commercially available portable clinical transcutaneous electrical stimulators (e.g. Empi TENS Unit).
Study NCT06053320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prism adaptation therapy (PAT) + Electrical stimulation (E-stim)
Description: PAT requires one to wear prism lenses while making arm-reaching movements toward visual targets. For treating left-sided neglect, a person wears the prism lenses that shift the visual field, including the images of the target and of one's own reaching arm, certain degrees to the right depending on the diopter of the lens (e.g., the 20-diopter lens shifts the visual field by 11.4 degrees). The visual system adapts over the repetitive practice of the arm reaching toward the target. The person eventually achieves success with a leftward movement reaching the actual target. Electrical stimulation (E-stim) involves parameters and settings commonly used in clinical practice as well as research for pain relief and other applications, commonly referred to as transcutaneous electrical nerve stimulation (TENS). TENS and E-stim are delivered using FDA-approved, commercially available portable clinical transcutaneous electrical stimulators (e.g. Empi TENS Unit).
Study NCT06053320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prism adaptation therapy (PAT) + Sham Stimulator
Description: Participants in the PAT with sham stim condition group will receive sham electrical stimulation treatment (electrodes will be attached but the stimulator will not be turned on) to the left upper limb with the same placement of electrodes while undergoing PAT.
Study NCT06053320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prism adaptation therapy (PAT) + Sham Stimulator
Description: Participants in the PAT with sham stim condition group will receive sham electrical stimulation treatment (electrodes will be attached but the stimulator will not be turned on) to the left upper limb with the same placement of electrodes while undergoing PAT.
Study NCT06053320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: After PAT, participants will complete multiple 30-seconds to 4-minute bouts of walking on the treadmill or overground at speeds ranging from self-selected to fast speeds (faster than comfortable self-selected speed), with rest breaks between bouts.
Study NCT06329622 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: low-protein diet + Ketosteril
Description: low-protein diet (0.6-0.8g protein/kg body weight/day) and Ketosteril 0.12 g/kg body weight/day will be prescribed with the target energy intake of 25-30kcal/kg body weight/day.
Study NCT06329622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low-protein diet
Description: low-protein diet (0.6-0.8g protein/kg body weight/day) with the target energy intake of 25-30kcal/kg body weight/day.
Study NCT06089746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIPT
Description: Coordinated suite of DME and training to support continuous maintenance of flexion posture during the 6 week trial.
Study NCT05725655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermotherapy
Description: Hot baths directly after an exercise session
Study NCT06380907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZL-1102 1% w/w gel BID for 16 weeks
Description: ZL-1102~1% w/w gel BID for 16 weeks
Study NCT06380907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZL-1102 3% w/w gel BID for 16 weeks
Description: ZL-1102 3% w/w gel BID for 16 weeks
Study NCT06380907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZL-1102 3% w/w gel QD for 16 weeks
Description: ZL-1102 3% w/w gel QD for 16 weeks
Study NCT06380907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ZL-1102 0% w/w gel BID for 16 weeks
Description: Vehicle 0% w/w gel BID for 16 weeks
Study NCT06380907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ZL-1102 0% w/w gel QD for 16 weeks
Description: Vehicle 0% w/w gel QD for 16 weeks
Study NCT05596591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused extracorporeal shockwave therapy
Description: High energy level shockwaves (between 0.28-0.60 mJ/mm\^2) will be focused over the subchondral bone with the bone marrow lesion, previously localized on MRI.
Study NCT06284278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing retraining
Description: 8 weeks diaphragmatic breathing training
Study NCT06284278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic stabilization exercise
Description: 8 weeks pelvic stabilization exercise training
Study NCT06284278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic anatomy education
Description: pelvic anatomy education
Study NCT05571800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango
Description: 120g of fresh Mango
Study NCT05571800 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200g isocaloric Granola Bar
Study NCT06502015 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: biomaker levels
Description: this study will discover and validate novel biomarkers (including blood, feces, bone marrow and lymph nodes etc al) of various neurological autoimmune diseases
Study NCT06192706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foldax Tria Aortic Valve
Description: Aortic Valve Replacement
Study NCT04947969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: This study will use German-made low-level laser pen (Al-Ga-As diode laser, 810nm, NIR, Physiolaser Olympic Basic, RJ laser). The parameters are power of 100mW, frequency of Bahr, apply on acupoint. Well will irradiate each point for 2 J. Each patient will receive this treatment six times for one week.
Study NCT06284278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic anatomy education
Description: pelvic anatomy education
Study NCT04947969 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: laser acupuncture
Description: This study will use German-made low-level laser pen (Al-Ga-As diode laser, 810nm, NIR, Physiolaser Olympic Basic, RJ laser). The parameters are power of 100mW, frequency of Bahr, apply on acupoint. Well will irradiate each point for 2 J. Each patient will receive this treatment six times for one week.
Study NCT05230082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
Study NCT05230082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
Study NCT06049693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Gluconate 300 MG
Description: Ferrous Gluconate 300 MG twice a day
Study NCT06361797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair augmented with whole bone marrow
Description: Bone marrow derived from the proximal humerus will be aspirated during the rotator cuff repair. At the end of the procedure, the aspirate will be injected back into the joint space.
Study NCT06361797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair augmented with whole bone marrow
Description: Bone marrow derived from the proximal humerus will be aspirated during the rotator cuff repair. At the end of the procedure, the aspirate will be injected back into the joint space.
Study NCT06361797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair augmented with concentrated bone marrow
Description: Bone marrow derived from the proximal humerus will be aspirated during the rotator cuff repair. This volume will be concentrated and, at the end of the procedure, the concentrate will be injected back into the joint space.
Study NCT06067893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patient receives dexmedetomidine for 48 hours post-operatively
Study NCT06067893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Patient receives normal saline for 48 hours post-operatively
Study NCT05463471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound sodium acetate ringer injection
Description: Quickly infuse 500ml of compound sodium acetate ringer injection for volume expansion within 20-30 minutes
Study NCT05463471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Quickly infuse 500ml of albumin for volume expansion within 20-30 minutes
Study NCT05679934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Stretching and strengthening exercises will be applied to the participants
Study NCT06313346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic capsules
Study NCT06313346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT05423249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Oral ferrous sulfate 325 mg once daily, containing 65 mg of elemental iron to treat non-anemic iron deficiency
Study NCT05546372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobiliary radiofrequency ablation (eRFA)
Description: Intraductal radiofrequency ablation of tumor prior to stent placement
Study NCT05546372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uncovered self-expanding metal stent (uSEMS)
Description: Intraductal placement of uncovered metal stent
Study NCT05546372 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncovered self-expanding metal stent (uSEMS)
Description: Intraductal placement of uncovered metal stent
Study NCT04739215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG [Farxiga]
Description: Dapagliflozin 10 mg / day oral
Study NCT04739215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One Placebo capsule daily oral
Study NCT06105645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIXI Medical Microdeep® Micro- Macro Depth electrodes
Description: It is a deep intracerebral electrode used in the pre-surgical diagnosis of certain drug-resistant epilepsies. It consists of micro- and macro-contacts and is designed for Stereo-ElectroEncephalography (SEEG) recording via the macro-contacts or micro-contacts and brief stimulation via the macro-contacts.
Study NCT06105645 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard electrodes
Description: Standard electrodes used usually during the SEEG
Study NCT06374979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Participants will receive an initial dose of 160 mg (two injections of 80 mg) ixekizumab subcutaneously at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12.
Study NCT05423249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prenatal
Description: Oral prenatal vitamin once daily for both groups
Study NCT05423249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prenatal
Description: Oral prenatal vitamin once daily for both groups
Study NCT05423249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docusate Sodium
Description: Oral docusate sodium 100 mg twice daily as needed, to treat constipation secondary to oral iron supplementation
Study NCT05423249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docusate Sodium
Description: Oral docusate sodium 100 mg twice daily as needed, to treat constipation secondary to oral iron supplementation
Study NCT05423249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid 500Mg Tab
Description: Oral ascorbic acid 500 mg daily, to improve absorption of oral iron
Study NCT05423249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo pill once daily
Study NCT05831891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib combined with Serplulimab
Description: Fruquintinib 5mg, qd, 2w on/1w off and Serplulimab 4.5mg/kg, IV drip, d1, q3w
Study NCT06455995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DEPTH
Description: All conditions will receive a reduced-energy, low-fat dietary prescription (1200-1500 kcal/d, \< 30% energy from fat), physical activity goals (> 200 min/wk of moderate- to vigorous-intensity physical activity \[MVPA\]) and a cognitive behavioral intervention. To minimize the effect of other eating temporal variables on outcomes, guidance on the eating window length and the number of eating occasions in the day will be consistent across all three conditions. Thus, the three conditions will be instructed to have their first eating occasion \< 60 minutes of awakening, and eat their three meals and one snack within a 12-hr eating window.
Study NCT06455995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DEPTH
Description: All conditions will receive a reduced-energy, low-fat dietary prescription (1200-1500 kcal/d, \< 30% energy from fat), physical activity goals (> 200 min/wk of moderate- to vigorous-intensity physical activity \[MVPA\]) and a cognitive behavioral intervention. To minimize the effect of other eating temporal variables on outcomes, guidance on the eating window length and the number of eating occasions in the day will be consistent across all three conditions. Thus, the three conditions will be instructed to have their first eating occasion \< 60 minutes of awakening, and eat their three meals and one snack within a 12-hr eating window.
Study NCT06455995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DEPTH-Morning
Description: Morning will also have time-based energy intake goals of 70% of kcal within the first 6 hrs of the eating window and 30% of kcal within the last 6 hrs of the eating window (a morning-loaded energy distribution).
Study NCT06455995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DEPTH-Evening
Description: Evening will also have time-based energy intake goals of 30% of kcal within the first 6 hrs of the eating window and 70% of kcal within the last 6 hrs of the eating window (an evening-loaded energy distribution).
Study NCT04847622 — intervention group
Intervention type: DRUG
Intervention: Remdesivir
Description: treated with Remdesivir
Study NCT05750004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer guided immediate implant placement
Description: Atraumatic extraction followed by immediate implant placement using safe angle position computer guided surgical stents, followed by customized healing abutments. after 3 months, Impressions for final prosthesis will be done
Study NCT06570642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Goals mHealth Intervention
Description: On days participants plan to exercise, they engage in two daily goal sessions (morning and evening). Morning sessions provide an activity goal for the day and ask the participant to create a plan, anticipate barriers, and brainstorm solutions for achieving this goal. The affect-based goal condition asks participants to engage in either (1) a type (50% of daily goals) or (2) a context (50% of daily goals) of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity (1) in a place; (2) in a social situation; or (3) while listening to something that makes them feel good. The intensity-based goal condition asks participants to maintain a certain target heart rate range during physical activity. Starting heart rate reflects the approximate age-adjusted heart rate max, with goals progressively increasing from 55% to 70% heart rate max.
Study NCT05220124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)
Description: 420mg Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) bid for 4 treatment cycles.